![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Comparative and Molecular Pharmacogenetics Laboratory (M.H.C., S.K., Q.H., S.X.D.) and Clinical Pharmacology Laboratory (L.L.v.M., D.J.G.), Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts; and BD Gentest (C.J.P.), Woburn, Massachusetts
(Received January 31, 2003; accepted June 12, 2003)
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
;
Coffman et al., 1998;
Barbier et al., 2000;
Innocenti et al., 2001).
Furthermore, this enzyme may play a substantial role in the metabolism of
endogenous substrates including steroids
(Turgeon et al., 2001) and
retinoids (Samokyszyn et al.,
2000). Consequently, interindividual variation in the functioning
of this enzyme, either as the result of environmental or genetic influences,
is likely to have important consequences for human health with respect to
susceptibility for adverse drug reactions and disease.
Characterization of the determinants of interindividual variation in UGT2B7 will require identification and validation of specific probe substrates for this enzyme that can be used (ideally) for both in vitro and in vivo studies. Morphine, codeine, and AZT are commonly used drugs that could potentially serve as UGT2B7 probes. However, the specificity of each of these drugs as UGT2B7 substrates has yet to be substantiated using either human tissues or subjects.
Current evidence indicates that UGT2B7 is the principal isoform mediating
morphine glucuronidation at both 3-hydroxyl and 6-hydroxyl positions in human
liver microsomes (HLMs) (Coffman et al.,
1997,
1998). Apparent
Km values for both morphine-3 and
morphine-6-glucuronidation by expressed UGT2B7 are similar to, although
somewhat lower (by 2- to 3-fold) than, apparent Km values
for HLMs. Furthermore, the ratio of morphine-3-glucuronidation to
morphine-6-glucuronidation activities measured using expressed UGT2B7 (about
7:1) is similar to ratios measured in HLMs (about 6:1)
(Yue et al., 1990; Coffman et
al., 1997,
1998). On the other hand,
detailed enzyme kinetic analysis of morphine-3-glucuronidation by HLMs has
indicated the possible contribution of multiple high- and low-affinity UGT
isoforms (Miners et al.,
1988). Very low morphine glucuronidation activities have also been
reported for UGT1A3 (Green et al.,
1998), but not for any other isoform.
Evidence that AZT and codeine are selective UGT2B7 substrates is much less
convincing. Screening of six different UGT2B isoforms showed AZT
glucuronidation activity for UGT2B7, but not for UGTs 2B4, 2B10, 2B11, 2B15,
or 2B17 (Barbier et al., 2000).
However, available UGT1A isoforms were not evaluated, and apparent
Km values for AZT glucuronidation by UGT2B7 were 24 to 160
times lower than values previously reported for HLMs
(Haumont et al., 1990;
Rajaonarison et al., 1991;
Resetar et al., 1991). Codeine
is glucuronidated by UGT2B7, but with activities that are less than 5% that of
morphine-3-glucuronidation (Coffman et al.,
1998). Again, apparent Km values for codeine
glucuronidation by UGT2B7 were also 2 to 15 times lower compared with HLMs
(Yue et al., 1990) As yet, no
other UGT isoforms are reported to have codeine glucuronidation activity.
A genetic polymorphism in the UGT2B7 gene has been identified that results
in either a histidine or tyrosine at amino acid 286 (H268Y) of the UGT2B7
protein, referred to as UGT2B7*1 or UGT2B7*2,
respectively (Bhasker et al.,
2000). The effect of this mutation on glucuronidation of a variety
of drugs has been studied by various groups using recombinant
UGT2B7*1 and UGT2B7*2. Significant differences between
variants in enzyme kinetic parameters or activities have not been observed for
most drugs evaluated, including morphine and codeine
(Coffman et al., 1998;
Innocenti et al., 2001).
However, the cell preparations used to determine these activities differed in
UGT2B7 protein content (approximately 2 times higher for UGT2B7*1
versus UGT2B7*2 by immunoblot), and it is not clear whether
activities were corrected for this difference. Using AZT as substrate, a third
group has shown no differences in apparent Km values
between variants; however, Vmax values were 2-fold higher
for UGT2B7*1 compared with UGT2B7*2 when normalized to
UGT2B7 protein content (Barbier et al.,
2000). The effect of this polymorphism on glucuronidation of
menthol, androsterone, and morphine has also been investigated using HLMs
(Bhasker et al., 2000).
Although there were no statistically significant differences in
glucuronidation activities between genotyped livers, a trend toward lower
morphine-3-glucuronidation activity in HLMs with the UGT2B7*2
allele was suggested.
In conclusion, AZT, morphine, and codeine are potentially useful substrate probes for the study of UGT2B7. The aim of this study was to evaluate the specificity of these drugs as UGT2B7 substrates using recombinant UGTs and HLMs (n = 54). The possible influence of the UGT2B7*2 polymorphism on UGT2B7 protein content and glucuronidation was also evaluated by genotyping the livers used to prepare the HLMs.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
).
Baculovirus-expressed UGTs 1A1, 1A3, 1A4, 1A6, 1A8, 1A9, 2B4, 2B7, 2B15, and
2B17 were obtained from BD Gentest (Woburn, MA), whereas UGTs 1A7 and 1A10
were from PanVera Corp. (Madison, WI). The glucuronidation activity of each of
the expressed UGTs was substantiated by the respective manufacturers using the
following substrates: bilirubin and estradiol (UGT1A1);
7-hydroxy-4-trifluoromethylcoumarin (UGTs 1A3, 1A8, 1A10, 2B4, and 2B15);
trifluoperazine (UGT1A4); 1-naphthol (UGTs 1A6 and 1A10); propofol (UGT1A9);
morphine (UGT2B7); octyl-gallate (UGT1A7); and eugenol (UGT2B17). In addition,
immunoblotting with an antibody specific for the conserved C-terminal region
of all UGT1A isoforms (WB-UGT1A; BD Gentest) showed that the content of
immunodetectable UGT protein was similar for all the expressed UGT1A isoforms
used.
Human Liver Microsomes. Liver samples from 54 individuals had been
obtained from various sources, including the International Institute for the
Advancement of Medicine (Exton, PA), the National Disease Research Interchange
(Philadelphia, PA), and the University of Minnesota Liver Tissue Procurement
and Distribution System (Minneapolis, MN). All livers were either intended for
transplantation but had failed to match the tissue or were normal tissue
adjacent to surgical biopsies. Donors were primarily white (n = 48),
but also included 4 African-Americans and 2 Hispanics. Other available
information included gender (16 females, 38 males) and age (median 41 years;
range 2 to 75 years). Microsomes were prepared by differential centrifugation
as previously described (Court and
Greenblatt, 1997b). The resultant pellet was reconstituted in 20%
glycerol, pH 7.5, 100 mM phosphate buffer, aliquoted and stored at -80°C.
Protein concentrations were measured using the bicinchoninic acid assay
(Pierce Chemical, Rockford, IL). The quality of the liver samples was
ascertained by reference to at least 10 other UGT and P450 enzyme activities
measured in this laboratory using the same set of liver samples. Livers that
consistently showed low activity values (>2-fold lower for all measured
activities) relative to the median activity value for the entire liver set
were excluded from further study.
AZT Glucuronidation Assay. An in vitro glucuronidation assay using
AZT as substrate was developed based on methods previously used in this
laboratory (Court and Greenblatt,
1997a,
b). Incubations (100 µl)
were performed in 50 mM phosphate buffer (pH = 7.5) at 37°C, 5 mM
MgCl2, and 5 mM UDPGA. AZT concentration was 500 µM for
correlation studies and between 100 µM and 10 mM for kinetic studies.
Alamethicin was also included in incubations at a concentration (50 µg/mg
of protein) determined in preliminary experiments to result in greatest
activation. Incubation time (up to 240 min) and protein concentration (up to
1.0 mg/ml) at a substrate concentration of 500 µM were also established in
preliminary studies to be within initial rate conditions. Incubations were
terminated by addition of 50 µl of acetonitrile, vortexed, and placed on
ice. After addition of the internal standard (50 nmol of 3-acetamidophenol),
the samples were centrifuged, and supernatants were transferred to HPLC tubes
and partially dried down in a vacuum oven at 45°C for 15 min before HPLC
analysis.
HPLC apparatus (Agilent Technologies 1100, Palo Alto, CA) consisted of an autoinjector, binary pump, column, and UV absorbance detector set at a wavelength of 266 nm. Chromatographic separation was performed using a C18 column (4.6 mm x 25 cm, 10 µm Synergi Hydro-RP; Phenomenex, Torrance, CA). The mobile phase was a mixture of 20 mM, pH 2.2, potassium phosphate buffer in water (solution A) and acetonitrile/5% water (solution B) at a flow rate of 1 ml/min. The solvent elution program consisted of an initial isocratic mobile phase mix (15% solution B) for 10 min, followed by a linear gradient from 15 to 50% solution B over 10 min. Analyte retention times were 7 min for AZT glucuronide, 8 min for 3-acetamidophenol (internal standard), and 11 min for AZT, and were confirmed by reference to authentic standards. Metabolite concentrations in the incubate were determined using a standard curve of peak area ratios (normalized to the internal standard) and generated by HPLC analysis of a series of known concentrations of AZT glucuronide dissolved in incubation buffer. Enzyme activities were then calculated by dividing metabolite concentration by protein concentration and incubation time and expressed as nanomoles per minute per milligram of protein.
Codeine Glucuronidation Assay. Codeine glucuronidation activities were also measured using a technique similar to that described for AZT glucuronidation with the following exceptions. Codeine concentration was 1 mM for correlation studies and between 50 µM and 10 mM for kinetic studies. Initial rate conditions were confirmed for up to 120 min of incubation time, and up to 1.0 mg/ml protein concentration at a substrate concentration of 500 µM. Alamethicin was included in incubations at a concentration of 100 µg/mg of protein. The internal standard was 400 nmol of AZT. After transfer of incubate supernatants to HPLC tubes, samples were completely dried down in a vacuum oven at 45°C for 30 min and then reconstituted with 100 µl of water. HPLC output was monitored using a UV detector set at a wavelength of 214 nm. The solvent elution program consisted of 10% solution B for the first 14 min, and then a linear gradient from 10 to 70% solution B over 6 min. Analyte retention times, confirmed by authentic standards, were 8 min for codeine-6-glucuronide, 10 min for codeine, and 16 min for the internal standard.
Morphine Glucuronidation Assay. Morphine glucuronidation activities were measured using a technique similar to that described for AZT glucuronidation with the following differences. Morphine concentration was 500 µM for correlation studies and between 100 µM and 20 mM for kinetic studies. Initial rate conditions were confirmed for up to 60 min of incubation time and up to 1.0 mg/ml protein concentration at a substrate concentration of 500 µM. The internal standard was 50 nmol of acetaminophen. After transfer of incubate supernatants to HPLC tubes, samples were completely dried down in a vacuum oven at 45°C for 30 min and then reconstituted with 100 µl of water. In addition to the UV detector set at a wavelength of 254 nm for detection of the internal standard, a serially connected fluorescence detector set at 215-nm excitation and 350-nm emission wavelengths was used to monitor morphine and morphine glucuronides. Solvent A was 20 mM potassium phosphate buffer at pH 4.5 (rather than pH 2.2). The solvent elution program consisted of a linear gradient from 0 to 5% solution B over 15 min, which increased to 50% solution B over the next 5 min. Analyte retention times, confirmed by authentic standards, were 5 min for morphine-3-glucuronide, 10 min for morphine-6-glucuronide, 12 min for morphine, and 17 min for the internal standard.
Other Glucuronidation Activities. Six other glucuronidation
activities (estradiol-3-glucuronidation, trifluoperazine glucuronidation,
serotonin glucuronidation, propofol glucuronidation, R- and
S-oxazepam glucuronidation) were measured using the same set of human
liver microsomes. The incubation conditions and HPLC assay method used have
been given in detail previously (Court et
al., 2002; Krishnaswamy et
al., 2003a). Substrate concentrations were 100 µM for
estradiol, 200 µM for trifluoperazine, 4 mM for serotonin, 100 µM for
propofol, and 100 µM for R- and S-oxazepam. These
concentrations were chosen to approximate Km values for
HLMs. Since propofol glucuronide and trifluoperazine glucuronide were not
available, the identity of glucuronide HPLC peaks was verified by HPLC-mass
spectrometry (Agilent Technologies 1100 MS), and glucuronide concentrations
were determined using a standard curve generated using the substrate, assuming
similar UV absorbance.
Enzyme Kinetic Analysis. Nonlinear least-squares regression
(GraphPad Prism version 3.00 for Windows; GraphPad Software Inc., San Diego,
CA) was used to fit the appropriate enzyme kinetic model to substrate
concentration (S) and velocity (V) data. The models were
chosen initially based on the appearance of Michaelis-Menten and Eadie-Hofstee
plots. These included the simple Michaelis-Menten model (eq. 1) and the
uncompetitive substrate inhibition model (eq. 2):
 | (1) |
 | (2) |
). The model chosen to best represent the data were based on a
number of criteria, including visual inspection of data plots
(Michaelis-Menten and Eadie-Hofstee), distribution of residuals, size of the
sum of squared residuals, and the standard error of the estimates. All kinetic
parameters are presented as a regression parameter estimate ± the
standard error of the estimate.
Nonspecific Microsomal Binding. Nonspecific binding of AZT, codeine,
and morphine to pooled human liver microsomes was quantified using a
modification of an ultrafiltration method described previously (Yao et al.,
2001,
2003). Briefly, tubes were
prepared containing microsomes (1 mg/ml) and substrate (100 µM) in 0.5 ml
of 50 mM phosphate buffer (pH 7.5) and incubated at 37°C for 2 h. Control
incubations containing substrate and buffer without microsomes were used to
assess recovery. The incubate was then applied to a centrifugal
ultrafiltration device (Ultrafree-MC 10K MW cutoff; Millipore Corporation,
Bedford, MA) and centrifuged at 5,000g until 20 to 30% of the initial
volume had been filtered (approximately 5–20 min). Substrate
concentrations were then determined in upper and lower reservoirs by HPLC as
described above. The unbound fraction (fu) was calculated
as the ratio of the filtered versus unfiltered drug concentration adjusted for
recovery.
UGT2B7 Protein Content. The relative content of UGT2B7 protein in hepatic microsomes from the liver bank was determined by adapting an immunoblotting method described previously (Court et al., 2001). Briefly, 4 to 50 µg of microsomal protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 4 to 15% gradient gel (Bio-Rad, Hercules, CA). Proteins were then electrophoretically transferred to polyvinyl difluoride membrane (Immobilon-P, Millipore Corporation), blocked in 10% powdered nonfat milk in TBS-Tween (0.15 M NaCl, 0.04 M Tris, pH 7.7, and 0.1% Tween 20) and then incubated in TBS-Tween/1% milk containing a 1:1,000 dilution of a polyclonal antipeptide UGT2B7 antibody (WB-UGT2B7; BD Gentest). After washing, the blots were incubated in a 1:10,000 dilution of horseradish peroxidase-conjugated secondary antibody (Sigma-Aldrich) and washed, and chemiluminescence reagent was applied (Super Signal; Pierce Chemical). Blots were imaged (Kodak Image Station 440CF; Eastman Kodak Co., Rochester, NY), and bands were quantified using Kodak 1D Image Analysis Software (Eastman Kodak Co.). The linearity of the measurements under the conditions used was established by loading serial dilutions of microsomes from high- and low-AZT glucuronidation activity livers and recombinant UGT2B7. Each blot contained a standard curve generated by using serial dilutions of UGT2B7. After normalizing for microsomal protein loading, values were expressed relative to the liver with the lowest UGT2B7 content.
UGT2B7 Genotyping. Livers were genotyped for the UGT2B7*2 polymorphism by PCR-RFLP analysis of genomic DNA and confirmed by direct sequencing of PCR product. Briefly, genomic DNA was prepared from liver tissue by DNAZOL extraction (Invitrogen, Carlsbad, CA). Typical 50-µl PCR reactions contained 100 ng of genomic DNA, 2 mM MgCl2, 0.2 mM dNTPs, 10 µl of 10x PCR buffer, primers, and 2.5 U of TaqDNA polymerase (Platinum Taq; Invitrogen). Amplification primers included a sense primer (PRI-122, 5'-TTATGATTATGAGCATACTGATGC-3') and an antisense primer (PRI-123, 5'-TACTTGCACATATTCTATCTTTTG-3'). PCR was performed in a thermal cycler (GeneAmp 9600; Applied Biosystems, Foster City, CA) using an initial denaturation cycle of 94°C for 4 min, then 40 cycles of 94°C for 30 s, 62°C for 30 s, and 72°C for 30 s, followed by a final extension cycle of 72°C for 15 min. An aliquot (10 µl) of the resultant 829-base pair PCR product was then digested with 4 units of Fok I (New England Biolabs, Beverly, MA) in a final 20-µl volume for 60 min at 37°C. Digestion fragments were then analyzed by electrophoresis in an ethidium bromide-stained 1.5% agarose gel. Three Fok I sites are present in the UGT2B7*1 allele PCR product, which result in 112-, 150-, 221-, and 346-bp fragments after digestion (Fig. 1). The UGT2B7*2 allele eliminates one of the Fok I sites (between the 112- and 346-bp fragments) with resultant 150-, 221-, and 458-bp fragments with digestion. The presence of both alleles in heterozygous livers results in five fragments (112, 150, 221, 346, and 458 bp). This assay was confirmed by direct sequencing (ABI Prism 3100; Applied Biosystems) of the initial 829-bp PCR product from 10 representatives of each genotype using a separate sequencing primer (PRI-124, 5'-CCTGTCAGGAAGACCCACTA-3').
|
Statistical Analysis. Statistical analyses were performed using the Sigmastat software package (SPSS Science, Chicago, IL). All activities were measured in duplicate and averaged. The potential influence of UGT2B7 genotype on UGT2B7 protein content and glucuronidation activities was evaluated by Kruskal-Wallis one-way ANOVA on ranks. A P value less than or equal to 0.05 was considered statistically significant. Spearman correlation analysis was used to examine the relationships between UGT2B7 protein content and each of the glucuronidation activities measured. For these analyses, a Spearman correlation coefficient (rs) value greater than or equal to 0.5 with a P value of less than 0.001 was considered statistically significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
Comparative Enzyme Kinetics. Enzyme kinetic studies were performed with AZT, morphine, and codeine using expressed UGT2B7 and HLMs (pooled from 54 donors). All data were well described by the simple Michaelis-Menten model (Fig. 3), except for codeine glucuronidation by UGT2B7 which was best described by the uncompetitive substrate inhibition model (Fig. 3B). Comparing HLMs with UGT2B7 for all activities, the enzyme kinetic parameters for AZT glucuronidation were the most similar with Km values of 1.4 ± 0.17 mM and 0.77 ± 0.16 mM, respectively, and Vmax values of 0.53 ± 0.021 nmol/min/mg of protein and 0.21 ± 0.012 nmol/min/mg of protein, respectively, representing about a 2- to 2.5-fold difference. For morphine-3-glucuronidation, enzyme kinetic values in HLMs were 4- to 6-fold higher compared with expressed UGT2B7, with Km values of 4.3 ± 0.52 mM and 0.67 ± 0.044 mM, respectively, and Vmax values were 2.7 ± 0.13 nmol/min/mg of protein and 0.65 ± 0.11 nmol/min/mg of protein, respectively. A smaller (3- to 4-fold) disparity was observed for morphine-6-glucuronidation with Km values for HLMs and UGT2B7 of 2.4 ± 0.22 mM and 0.63 ± 0.075 mM, respectively, and Vmax values of 0.28 ± 0.008 nmol/min/mg of protein and 0.099 ± 0.003 nmol/min/mg of protein, respectively. The greatest difference (6- to 9-fold) in kinetic values was seen for codeine glucuronidation with Km values for HLMs and UGT2B7 of 2.6 ± 0.20 mM and 0.40 ± 0.040 mM, respectively, and Vmax values of 0.63 ± 0.033 nmol/min/mg of protein and 0.074 ± 0.004 nmol/min/mg of protein, respectively.
|
Nonspecific Microsomal Binding. There was essentially no binding of AZT (fu = 0.95 ± 0.07), morphine (fu = 1.04 ± 0.10), or codeine (fu = 1.01 ± 0.09) to pooled HLMs measured using 100 µM substrate concentration and 1 mg/ml protein concentration.
Correlational Analyses. Correlational analyses (Table 1 and Fig. 4) with relative UGT2B7 protein content as the dependent variable showed a relatively strong relationship with AZT glucuronidation (rs = 0.77, P < 0.001) and weaker but significant correlations with morphine-3-glucuronidation (rs = 0.50, P < 0.001) and morphine-6-glucuronidation (rs = 0.51, P < 0.001). No significant correlations were found with codeine glucuronidation (rs = 0.33, P = 0.015) or any other glucuronidation activity measured (rs < 0.43, P > 0.001).
|
|
Effect of UGT2B7*2 Genotype. Genotyping of the entire set
of human livers (n = 54) for the UGT2B7*1/*2 (H268Y)
polymorphism identified 11 individuals homozygous for the UGT2B7*1
allele, 25 heterozygous individuals, and 16 individuals homozygous for the
UGT2B7*2 allele. A genotype could not be unambiguously assigned to
one liver (HL47). These genotype frequencies were consistent with
Hardy-Weinberg equilibrium (
2 = 0.00019, P = 1.00).
Allele frequencies were 0.45 for UGT2B7*1 and 0.55 for
UGT2B7*2.
As shown in Fig. 5, no significant differences between genotype groups could be discerned by ANOVA for AZT glucuronidation (P = 0.29), morphine-3-glucuronidation (P = 0.23), morphine-6-glucuronidation (P = 0.65), or codeine glucuronidation (P = 0.37). Similarly, there were no differences in relative microsomal UGT2B7 protein content (P = 0.25) or AZT glucuronidation normalized to UGT2B7 content (P = 0.37) among UGT2B7 genotype groups (Fig. 6).
|
|
Enzyme kinetics for each UGT2B7 substrate were also determined for individual livers genotyped as homozygous UGT2B7*1 (LV12) and homozygous UGT2B7*2 (LV43) (Fig. 7). Km values for LV12 and LV43, respectively, were essentially identical for AZT glucuronidation (0.53 ± 0.03 and 0.51 ± 0.04 mM), codeine glucuronidation (1.3 ± 0.16 and 1.2 ± 0.16 mM), morphine-3-glucuronidation (1.1 ± 0.15 and 1.2 ± 0.14 mM), and morphine-6-glucuronidation (1.7 ± 0.36 and 2.0 ± 0.31 mM). Higher Vmax values for LV12 compared with LV43, respectively, were observed for AZT glucuronidation (0.92 ± 0.01 versus 0.39 ± 0.01 nmol/min/mg of protein), morphine-3-glucuronidation (13 ± 0.5 versus 5.7 ± 0.2 nmol/min/mg of protein), morphine-6-glucuronidation (2.1 ± 0.14 versus 1.1 ± 0.06 nmol/min/mg of protein), but not for codeine glucuronidation (1.0 ± 0.01 versus 0.95 ± 0.01 nmol/min/mg of protein).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
), AZT
glucuronidation was not observed for any of the UGT1A isoforms evaluated.
However, in contrast to that study, low but measurable AZT glucuronidation
activities were seen with UGT2B4 and 2B17, in addition to UGT2B7. This
difference might be the result of relatively greater assay sensitivity (5
pmol/min/mg of protein in this study, but not given in the previous study) or
perhaps higher specific activity of the recombinant preparations used
(baculovirus-insect cells in this instance versus HEK-293 cells in the
previous study).
Comparisons of enzyme kinetic parameters between HLMs and recombinant
UGT2B7 were made to further evaluate the relative contribution of UGT2B7 to
substrate glucuronidation. The ideal UGT2B7 probe substrate would be
glucuronidated solely by UGT2B7 and, therefore, should have an identical
apparent Km and a relatively high Vmax
value for recombinant UGT2B7 compared with HLMs. This was recently found to be
the case for serotonin glucuronidation by HLMs and UGT1A6
(Krishnaswamy et al., 2003a).
Based on the results of the present study, AZT glucuronidation also appears to
fit these criteria in that Km values were essentially
identical for UGT2B7 (0.77 mM) and livers LV12 and LV34 (0.53 and 0.51 mM),
although somewhat higher for pooled HLMs (1.4 mM). In contrast, more
substantial differences in Km values between HLMs and
UGT2B7 were observed for morphine-3-and morphine-6-glucuronidation (2- to
6-fold higher) and codeine glucuronidation (3- to 6-fold higher). Such
differences probably reflect the contribution of low-affinity isoforms in
addition to UGT2B7 to glucuronidation in HLMs. Consequently, relatively high
substrate concentrations should be avoided to minimize the contribution of
these other isoforms to the measured activity.
Although we used identical protein concentrations for the kinetic analyses,
the differences in Km values between HLMs and expressed
UGT preparations might also be explained by differential nonspecific
microsomal binding (Venkatakrishnan et al.,
2000,
2001). In particular, there
could be greater binding of substrate (AZT, morphine, or codeine) to the
microsomal matrix of HLMs than expressed UGTs resulting in a higher apparent
Km for HLMs, despite a similar unbound
Km for the two preparations. However, this was not the
case, in that no binding (fu > 0.95) was observed for
AZT, morphine, and codeine using an ultrafiltration method, which is in
agreement with values (fu > 0.80) previously reported
for these same compounds using an equilibrium dialysis method
(Boase and Miners, 2002;
Soars et al., 2002).
Typically, high nonspecific binding is characteristic of either basic or
highly lipophilic drugs (McLure et al.,
2000).
AZT glucuronidation also showed the highest correlation with UGT2B7 protein
content measured in the same set of HLMs with a correlation value
(rs = 0.77) essentially identical to the value
(rs = 0.77) we previously reported for
correlation between serotonin glucuronidation and UGT1A6 protein content in
HLMs (Krishnaswamy et al.,
2003a). Lower but significant correlation values were also found
between UGT2B7 protein and morphine glucuronidation
(rs = 0.50–0.51), but not for codeine
glucuronidation or any other glucuronidation activity measured
(rs < 0.5). Estradiol-3 glucuronidation
(Fisher et al., 2000;
Patten et al., 2001),
trifluoperazine glucuronidation (Dehal et
al., 2001), serotonin glucuronidation
(Krishnaswamy et al., 2003a),
propofol glucuronidation (Ebner and
Burchell, 1993), and S-oxazepam glucuronidation
(Court et al., 2002) were
measured as indicators of glucuronidation by UGT1A1, 1A4, 1A6, 1A9, and 2B15,
respectively. Interestingly, R-oxazepam glucuronidation had the
highest correlation with UGT2B7 protein (rs =
0.42) after AZT and morphine glucuronidation. R-oxazepam was recently
shown to be glucuronidated by UGT2B7 as well as UGT1A9
(Court et al., 2002).
Both morphine-3-glucuronidation and morphine-6-glucuronidation were
relatively poor indicators of UGT2B7 protein content under the assay
conditions used. However, it is possible that the contribution of UGT2B7 to
these activities (and isoform selectivity of the activities) might be enhanced
at lower morphine concentrations (less than 500 µM), since the apparent
Km of UGT2B7 is low relative to the Km
of HLMs. Indeed, plasma morphine concentrations in patients following a
standard clinical dose of this drug rarely exceed 300 ng/ml, or about 1 µM
(Cepeda et al., 2001).
Unfortunately, methodological limitations in the sensitivity of the current
morphine glucuronidation assay precluded such an analysis in this study.
Codeine clearly is not a selective probe substrate for UGT2B7, given that
recombinant UGT2B4 was equally (or perhaps more) efficient in this activity.
Furthermore, there were relatively large differences in enzyme kinetic
parameters between HLMs and recombinant UGT2B7, and there was no significant
correlation between UGT2B7 protein content and codeine glucuronidation
activity. Involvement of UGT2B4 in codeine glucuronidation, as well as
glucuronidation of the other drugs evaluated in this study (AZT and morphine),
is a novel finding but not surprising considering the high degree of amino
acid sequence homology between UGTs 2B7 and 2B4. Sequence polymorphisms of the
UGT2B4 gene coding region have been reported and could potentially contribute
to interindividual variability of UGT2B4 substrates such as codeine
(Levesque et al., 1999).
Previous studies indicate that the UGT2B7*2 polymorphism could
negatively impact UGT2B7-mediated glucuronidation through an effect on
microsomal UGT2B7 protein content or specific activity
(Coffman et al., 1998;
Barbier et al., 2000;
Bhasker et al., 2000). However,
the results from this study do not support this contention. There was no
effect of UGT2B7*2 genotype on glucuronidation of any of the UGT2B7
substrates by HLMs. Furthermore, there were no differences in either UGT2B7
protein content or UGT2B7 specific activity (estimated by dividing AZT
glucuronidation activity by UGT2B7 protein content) related to
UGT2B7*2 genotype. These findings are supported by a recent study
that showed no effect of the UGT2B7*2 polymorphism on the ratios of
morphine glucuronide (either morphine-3-glucuronide or morphine-6-glucuronide)
to morphine concentration in the plasma of patients receiving slow-release
oral morphine (Holthe et al.,
2002). Consequently, other genetic and environmental factors are
likely to explain interindividual variability in glucuronidation of AZT,
morphine, and codeine.
In conclusion, results from this study indicate that both AZT and morphine can serve as isoform-selective probe substrates for UGT2B7, although AZT appears to be more selective as a probe substrate than morphine. Codeine is not a probe substrate for UGT2B7 probably because of significant glucuronidation by UGT2B4. The UGT2B7*2 polymorphism is not a determinant of AZT, morphine, and codeine glucuronidation in HLMs.
|
Footnotes |
|---|
1 Abbreviations used are: UGT, UDP-glucuronosyltransferase; AZT,
3'-azido-3'-deoxythymidine; HLMs, human liver microsomes; HPLC,
high-performance liquid chromatography; UDPGA, UDP-glucuronic acid; TBS,
Tris-buffered saline; PCR, polymerase chain reaction; RFLP, restriction
fragment length polymorphism; dNTPs, deoxynucleoside-5'-triphosphate;
ANOVA, analysis of variance; bp, base pair. 
Address correspondence to: Michael H. Court, Comparative and Molecular Pharmacogenetics Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University, 136 Harrison Avenue, Boston, MA 02111. E-mail: michael.court{at}tufts.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  V. Uchaipichat, A. Galetin, J. B. Houston, P. I. Mackenzie, J. A. Williams, and J. O. Miners Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites Mol. Pharmacol., October 1, 2008; 74(4): 1152 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-X. Liu, Y. Liu, J.-W. Zhang, W. Li, H.-T. Liu, and L. Yang UDP-Glucuronosyltransferase 1A6 Is the Major Isozyme Responsible for Protocatechuic Aldehyde Glucuronidation in Human Liver Microsomes Drug Metab. Dispos., August 1, 2008; 36(8): 1562 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rowland, K. M. Knights, P. I. Mackenzie, and J. O. Miners The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities Drug Metab. Dispos., June 1, 2008; 36(6): 1056 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohno, K. Kawana, and S. Nakajin Contribution of UDP-Glucuronosyltransferase 1A1 and 1A8 to Morphine-6-Glucuronidation and Its Kinetic Properties Drug Metab. Dispos., April 1, 2008; 36(4): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, D. Zhang, D. Cui, J. Gambardella, L. Ma, A. Barros, L. Wang, Y. Fu, S. Rahematpura, J. Nielsen, et al. Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism Drug Metab. Dispos., December 1, 2007; 35(12): 2270 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura Predominant Contribution of UDP-Glucuronosyltransferase 2B7 in the Glucuronidation of Racemic Flurbiprofen in the Human Liver Drug Metab. Dispos., July 1, 2007; 35(7): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura Comparison of Inhibition Potentials of Drugs against Zidovudine Glucuronidation in Rat Hepatocytes and Liver Microsomes Drug Metab. Dispos., April 1, 2007; 35(4): 602 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rowland, P. Gaganis, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 137 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wen, D. E. Martin, P. Bullock, K.-H. Lee, and P. C. Smith Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences Drug Metab. Dispos., March 1, 2007; 35(3): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bowalgaha, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners The Glucuronidation of {Delta}4-3-Keto C19- and C21-Hydroxysteroids by Human Liver Microsomal and Recombinant UDP-glucuronosyltransferases (UGTs): 6{alpha}- and 21-Hydroxyprogesterone Are Selective Substrates for UGT2B7 Drug Metab. Dispos., March 1, 2007; 35(3): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takeda, Y. Kitajima, Y. Ishii, Y. Nishimura, P. I. Mackenzie, K. Oguri, and H. Yamada INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE Drug Metab. Dispos., August 1, 2006; 34(8): 1277 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062. [Abstract] |
